MwanzoTMO • NYSE
add
Thermo Fisher Scientific Inc
Bei iliyotangulia
$ 565.32
Bei za siku
$ 554.20 - $ 569.40
Bei za mwaka
$ 385.46 - $ 610.97
Thamani ya kampuni katika soko
213.21B USD
Wastani wa hisa zilizouzwa
2.33M
Uwiano wa bei na mapato
32.79
Mgao wa faida
0.30%
Ubadilishanaji wa msingi
NYSE
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 11.12B | 4.94% |
Matumizi ya uendeshaji wa biashara | 2.45B | 0.99% |
Mapato halisi | 1.62B | -0.86% |
Kiwango cha faida halisi | 14.53 | -5.53% |
Mapato kwa kila hisa | 5.79 | 9.66% |
EBITDA | 2.82B | 5.75% |
Asilimia ya kodi ya mapato | 11.32% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 3.55B | -46.64% |
Jumla ya mali | 103.02B | 2.65% |
Jumla ya dhima | 51.87B | 1.17% |
Jumla ya hisa | 51.15B | — |
hisa zilizosalia | 375.71M | — |
Uwiano wa bei na thamani | 4.16 | — |
Faida inayotokana na mali | 5.25% | — |
Faida inayotokana mtaji | 6.21% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 1.62B | -0.86% |
Pesa kutokana na shughuli | 2.24B | 3.37% |
Pesa kutokana na uwekezaji | -4.12B | -15.23% |
Pesa kutokana na ufadhili | -632.00M | 46.89% |
Mabadiliko halisi ya pesa taslimu | -2.59B | -6.80% |
Mtiririko huru wa pesa | 1.47B | -21.49% |
Kuhusu
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1956
Makao Makuu
Tovuti
Wafanyakazi
125,000
